FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
“During the past year, we achieved several key milestones that we believe strengthen our position operationally and subsequently initiated a limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system. The new indication for the Upper GI space, along with several technological advancements in both devices are expected to strengthen our ability to penetrate the endoscopy market,” commented Mark Pomeranz, Chief Executive Officer. “We believe the EVS Gastro system opens up significant new market opportunities for our technology, especially in the emergent setting of upper GI bleeding. We have already seen positive results in this high acuity population. Following its initial launch, we received positive feedback on these latest devices in terms of easy of setup and better handling with our Flex Channel technology that has no oversleeve in both the upper and lower GI tract. We are in the process of moving existing accounts over to these new devices, which is expected to be completed by end of the first quarter of 2024 and will move on to targeting new accounts in the second quarter.”
“Over the last six months, we have been able to improve our balance sheet by reducing our debt, eliminating a historical royalty commitment and receiving an infusion of capital. We believe our ability to achieve all these milestones over the past year has created significant value in our business and put us in a strong position to seek strategic partnerships,” concluded Mr. Pomeranz.
Fourth Quarter and Recent Business Highlights
Financial Results for the Quarter and Year Ended December 31, 2023
The Company reported revenue of $64,000 for the fourth quarter 2023, compared to $109,000 for the same period last year. Revenues for the full year 2023 were $319,000 compared to $592,000 in 2022. Revenues were primarily derived from reorders and new customer orders of disposable sleeves.
For the three months ended December 31, 2023, the Company reported a net loss attributable to common shareholders of $2.8 million, or $4.48 per basic and diluted share, compared to a net loss attributable to common shareholders of $3.7 million, or $11.89 per basic and diluted share, for the same period last year.
For the year ended December 31, 2023, the Company reported a net loss attributable to common shareholders of $12.9 million compared to a net loss attributable to common shareholders of $18.6 million for the year ended December 31, 2022.
During the fourth quarter 2023, net cash used in operating activities and for the purchase of fixed assets was $1.9 million as compared to $4.0 million for the same period of 2022.
Net cash used in operating activities and for the purchase of fixed assets during the year ended December 31, 2023 totaled $11.3 million as compared to $17.7 million for the same period of 2022.
The Company reported $5.0 million in cash and cash equivalents as of December 31, 2023. This balance includes the fully funded credit facility with Kreos Capital, which has approximately $2.3 million due and outstanding as of December 31, 2023.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Motus GI Holdings, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share amounts) | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,958 | $ | 14,042 | ||||
| Accounts receivable | 76 | 59 | ||||||
| Inventory, current | 245 | 488 | ||||||
| Prepaid expenses and other current assets | 478 | 781 | ||||||
| Total current assets | 5,757 | 15,370 | ||||||
| Fixed assets, net | 992 | 1,325 | ||||||
| Inventory, non-current | 251 | 511 | ||||||
| Right-of-use assets | 210 | 428 | ||||||
| Other non-current assets | 13 | 13 | ||||||
| Total assets | $ | 7,223 | $ | 17,647 | ||||
| Liabilities and Shareholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 1,842 | $ | 1,969 | ||||
| Operating lease liabilities - current | 169 | 245 | ||||||
| Other current liabilities | 226 | 53 | ||||||
| Current portion of long-term debt, net of unamortized debt discount of $16 and $182, respectively | 1,033 | 2,532 | ||||||
| Total current liabilities | 3,270 | 4,799 | ||||||
| Contingent royalty obligation | - | 1,212 | ||||||
| Operating lease liabilities - non-current | 27 | 178 | ||||||
| Convertible note, net of unamortized debt discount of $0 and $108, respectively | - | 3,892 | ||||||
| Long-term debt, net of unamortized debt discount of $108 and $135, respectively | 1,239 | 4,589 | ||||||
| Total liabilities | 4,536 | 14,670 | ||||||
| Commitments and contingent liabilities (Note 9) | ||||||||
| Shareholders’ equity | ||||||||
| Preferred stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding | - | - | ||||||
| Common stock $0.0001 par value; 115,000,000 shares authorized; 1,547,042 and 310,494 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | - | - | ||||||
| Additional paid-in capital | 156,905 | 144,328 | ||||||
| Accumulated deficit | (154,218 | ) | (141,351 | ) | ||||
| Total shareholders’ equity | 2,687 | 2,977 | ||||||
| Total liabilities and shareholders’ equity | $ | 7,223 | $ | 17,647 | ||||
| Motus GI Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Comprehensive Loss (Unaudited, in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Twelve months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 64 | $ | 109 | $ | 319 | $ | 592 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue - sales | 19 | 32 | 81 | 198 | ||||||||||||
| Cost of revenue - impairment of inventory | 267 | 439 | 488 | 598 | ||||||||||||
| Research and development | 561 | 1,350 | 3,467 | 5,611 | ||||||||||||
| Sales and marketing | 244 | 871 | 1,611 | 4,425 | ||||||||||||
| General and administrative | 1,445 | 1,444 | 6,579 | 7,611 | ||||||||||||
| Total costs and expenses | 2,536 | 4,136 | 12,226 | 18,443 | ||||||||||||
| Operating loss | (2,472 | ) | (4,027 | ) | (11,907 | ) | (17,851 | ) | ||||||||
| Gain on change in estimated fair value of contingent royalty obligation | - | 577 | 103 | 548 | ||||||||||||
| Loss on extinguishment of debt | (284 | ) | - | (284 | ) | - | ||||||||||
| Finance expense, net | (54 | ) | (251 | ) | (761 | ) | (1,252 | ) | ||||||||
| Foreign currency gain (loss) | 5 | 19 | (18 | ) | (42 | ) | ||||||||||
| Net loss | $ | (2,805 | ) | $ | (3,682 | ) | $ | (12,867 | ) | $ | (18,597 | ) | ||||
| Basic and diluted loss per common share: | $ | (4.48 | ) | $ | (11.89 | ) | $ | (15.89 | ) | $ | (86.15 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 626,313 | 309,788 | 809,506 | 215,863 | ||||||||||||
| Last Trade: | US$0.00 |
| Daily Change: | -0.17 -100.00 |
| Daily Volume: | 6,900 |
February 22, 2024 February 21, 2024 November 13, 2023 November 10, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
